Johnson & Johnson Drug Shows Improved Mania Symptoms in Bipolar Patients
In brief
Caplyta’s Phase 3 success signals a promising new treatment for acute bipolar mania, potentially boosting JNJ’s earnings and market position in psychopharmacology.
ClearTape summarizes context in-app. For the full publisher article, use Read original source above.